Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sitagliptin - Merck & Co

Drug Profile

Sitagliptin - Merck & Co

Alternative Names: Glactiv; Januvia; MK-0431; MK-431; ONO-5435; Sitagliptin phosphate - Merck & Co; Tesavel; Xelevia

Latest Information Update: 07 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co; Merck Sharp & Dohme
  • Developer Banyu; Merck & Co; Merck Sharp & Dohme; Ono Pharmaceutical; University of Colorado at Denver; Washington University School of Medicine
  • Class Antihyperglycaemics; Fluorobenzenes; Ketones; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 30 Sep 2022 US Court of Appeals for the Federal Circuit rules in favor of Merck in a patent infringement suit against Viatris for sitagliptin phosphate
  • 23 Sep 2022 Merck enters into patent litigation settlement agreements with multiple generic companies
  • 23 Sep 2022 US District Court rules in favor of Merck in a patent infringement suit against Viatris for sitagliptin phosphate
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top